We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current HIK market cap is 4.23B. The company's latest EPS is USD 0.8685 and P/E is 22.08.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.21B | 2.34B | 2.55B | 2.52B | 2.88B |
| Operating Income | 482M | 613M | 620M | 287M | 399M |
| Net Income | 486M | 431M | 421M | 188M | 192M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 3.93B | 4.14B | 4.37B | 4.47B | 4.68B |
| Total Liabilities | 1.8B | 1.99B | 1.91B | 2.32B | 2.47B |
| Total Equity | 2.13B | 2.15B | 2.47B | 2.15B | 2.21B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 472M | 464M | 638M | 530M | 608M |
| Investing | -151M | -283M | -238M | -607M | -333M |
| Financing | -155M | -298M | -287M | -58M | -337M |
| Market Cap | 4.23B |
| Price to Earnings Ratio | 22.08 |
| Price to Sales Ratio | 1.47 |
| Price to Cash Ratio | 20.68 |
| Price to Book Ratio | 1.92 |
| Dividend Yield | - |
| Shares Outstanding | 221.08M |
| Average Volume (1 week) | 427.59k |
| Average Volume (1 Month) | 429.26k |
| 52 Week Change | 6.16% |
| 52 Week High | 2,222.00 |
| 52 Week Low | 1,711.00 |
| Spread (Intraday) | 2 (0.1%) |
| Company Name | Hikma Pharmaceuticals Plc |
| Address |
1 new burlington place london W1S 2HR |
| Website | https://www.hikma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
